Trial · NCT04571489
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
NCT04571489, Phase 2, Unknown, Lee's Pharmaceutical Limited
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer. Trials, record NCT04571489. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04571489
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- NCT number
- NCT04571489
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Lee's Pharmaceutical Limited
- Conditions
- Pancreatic Cancer
- Interventions
- Gimatecan, tegafur, gimeracil and oteracil potassium, gemcitabine
- First posted
- 2020-10-01
- Last updated
- 2020-10-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months. | The 2-year progression free survival of the whole group. |
| Secondary | Overall survival (OS) | From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months. | The 2-year overall survival of the whole group. |
| Secondary | Objective response rate (ORR) | To evaluate objective response rate every 6 weeks after the initiation of chemotherapy, up to 24 months. | Percentage of patients with objective response assessed by best overall. |
| Secondary | Duration of Response (DoR) | First documented CR or PR, whichever is first recorded until the first assessment of PD, assessed up to 24 months. | The duration is measured from the first documented response (CR or PR, whichever is first recorded) until the first assessment of Progressive Disease (PD). |
| Secondary | Disease control rate (DCR) | To evaluate disease control rate every 6 weeks after the initiation of chemotherapy, up to 24 months. | Percentage of patients with disease control as assessed by best overall. |
| Secondary | Patient-reported outcome (PRO) | To evaluate every 6 weeks after the initiation of chemotherapy, up to 24 months. | Change from baseline assessed according to the quality of life questionnaire C30. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04571489
GET https://conductscience.org/api/trials/v1/NCT04571489/registered